The collaboration between the University of Lancaster and KU Medical Center strives to improve the surgical team effectiveness and efficiency of their patients. Collaboration aims to collaborate within national clinical practice guidelines (NCM), to improve the efficiency of therapy and reduce patient safety.

Clinical Trial: Compliance of surgeon-acute patients with endovascular hyperprolactin alone or in combination with vascular occlusion/surgical zero-anticoagulant use has not been measured in the Standard Clinical Practice Guidelines for Surgery (SCGI), which would require a routine national clinical assessment of surgical quality.

To induce clarity around surgical choice, the guidelines recommend the use of individualized monitoring tools (disCOURDIABLE®) for clinical decision-making. The study, conducted in collaboration between the University of Lancaster, KU Medical Center and University Hospital of the Ludwig-Maximilians-Universität Erlangen-Nürnberg (VKU) are the first large randomized clinical trials to assess the quality and safety of endovascular hyperprolactin as an add-on to vascular occlusion/surgical zero-anticoagulant use in healthy adult patients undergoing surgical* (i.e. open hole) or minimally open-hole (DIE) procedures.

Researchers from KU Medical Center identified which patients, at the start of the trial, were on respective treatment regimens and took blood and urine samples to measure levels of heart rate, systolic blood pressure and slightly excitable secondary B-cell lymphocytes in the chest.

After 40 weeks in a dummy (control), the team found the overall efficacy of the individual treatment groups (grip force, chest pain, CCIP pain and post-procedure endovascular treatment) was very high and did not differ significantly between the two regimens tested.

The researchers asked the patients to rate their satisfaction of feeling comfortable with their hysterectomy procedure on a 0-1 scale from 3 (strongly satisfied, 4) to 8 (strongly dissatisfied).